By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Fresh data on Biotechnology are presented in a new report. According to news reporting originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "Monoclonal antibodies (mAbs) or their derivatives are often used as the targeted ligands in the ligand targeted liposomes (LTLs). LTLs modified with mAbs or their derivatives are defined as immunoliposomes."
Our news editors obtained a quote from the research from International Joint Cancer Institute, "Immunoliposomes can be designed to improve the pharmacological properties of conventional drugs. The development of immunoliposomes, which perfectly combines antibody engineering and liposomes, is becoming a possible state-of-the-art in liposome research. This review discusses the recent characterization and therapeutic effects of immunoliposomes in cancer therapy. The recent advances in the field of immunoliposomes for the treatment of cancer are summarized as follows: antibody engineering, current antibody conjugation strategies, characterization and therapeutic effects of immunoliposomes and the future perspective of immunoliposomes. Although antibody targeted immunoliposomes are being developed rapidly, there has been still a number of hot spots in research that require sustained effort for success."
According to the news editors, the research concluded: "It is reasonable to predict that immunoliposomes will be approved for clinic use, and patients will benefit much from this cancer targeted therapy."
For more information on this research see: Antibody-targeted immunoliposomes for cancer treatment. Mini Reviews In Medicinal Chemistry, 2013;13(14):2026-35 (see also Biotechnology).
The news editors report that additional information may be obtained by contacting J. Gao, International Joint Cancer Institute, the Second Military Medical University, Shanghai, People's Republic of China. Additional authors for this research include H. Chen, H. Song, X. Su, F. Niu, W. Li, B. Li, J. Dai, H. Wang and Y. Guo.
Keywords for this news article include: Asia, Antibodies, Biotechnology, Shanghai, Oncology, Liposomes, Immunology, Blood Proteins, Immunoglobulins, Cancer Gene Therapy, Drug Delivery Systems, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC